|Publication number||US3814097 A|
|Publication date||4 Jun 1974|
|Filing date||24 Jan 1973|
|Priority date||14 Feb 1972|
|Also published as||DE2305989A1|
|Publication number||US 3814097 A, US 3814097A, US-A-3814097, US3814097 A, US3814097A|
|Inventors||D Ganderton, Ainsh J Mc, G Varney|
|Original Assignee||Ici Ltd|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (9), Referenced by (234), Classifications (17)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Paten 1191 Ganderton et al.
1451 June 4, 1974' DRESSING Inventors: David Ganderton; James McAinsh;
Gordon Varney, all of Macclesfield, England Imperial Chemical Industries Limited, London, England Filed: Jan. 24, 1973 Appl. No.: 326,474
 Foreign Application Priority Data Feb. 14, 1972 Great Britain 006692/72 US. Cl 128/268, 128/2 W, 128/260,
I 128/253 Int. Cl. A6" 7/02 Field Search 128/2 W, 260, 268, 253,
References Cited 7 UNlTED STATES PATENTS 3/1962 Baron 128/214 F Kravitz et a1. 128/253 3,062,212 1 1/1962 3,072,122 1/1963 Rosenthul 128/253 R25,637 8/1964 Kravitz et al. 128/253 3,167,073 1/1965 Rosenthal 1. 128/253 3,416,530 12/1968 Ness 128/260 3,545,439 12/1970 Duncan... 128/260 3,565,075 2/1971 Jerry 128/268 3,595,231 7/1971 Pistor 128/253 Primary ExtzminerAldrich F. Medbery Attorney, Agent, or Firm-Cushman, Darby & Cushman ABSTRACT A dressing for administering a drug through the skin of a host comprising a reservoir for the drug and, located between the reservoir and the skin of the host when the dressing is in use. a pad provided with tiny spikes. These tiny spikes augment the absorption of the drug without causingirritution- 10 Claims, 2 Drawing Figures PATENTEDJUN 41914 III HHIIIIIIVIIIIIIILLLL IHIH'HHHHIHHII This invention relates to a dressing for application to the skin. In particular, it relatesto a dressing the primary use of which is not toprotect, or apply medication to, a wound or lesion, but in the administration of a pharmacologically active material to man or an animal.
It is well-known that pharmacologically active materials, including drugs and medicinal products, may be administered to man or animals by a variety of routes of which the most important are by mouth, by injection or topically. However, topical application does not usually result in the pharmacologically active material becoming distributed throughout the body'of the host, and not all pharmacologically active materials may be administered by mouth. Injection is an inconvenient method of administration, especially if it has to be done frequently, and there is a need for an alternative.
It is an object of the present invention to provide a dressing which, on application to the skin, will enable a pharmacologically active material to pass from a reservoir through the stratum corneum and be adsorbed sufficiently to become distributed throughout the body of the host. An essential component of this dressing is a pad or plaster, provided with minute spikes, which is located in contact with the skin.
According to the invention therefore there is provided a pad comprising a sheet of material provided with tiny fibres projecting from at least one face of the sheet, the fibres being sufficiently rigid and projecting sufficiently from one face of the sheet such that upon application of that face of the sheet to the skin of a host, the fibres penetrate the skin to permit a liquid formulation of a pharmacologically active material, when present, to pass into the host and become distributed throughout the body of the host.
The inventionthus provides the basis of a dressing which can be used as an alternative to injection for the administration of a pharmacologically active material.
The number of fibres projecting from a unit area of the sheet may vary widely, but in the preferred embodiments, a multitude of fibres are used. Thus, for example, while some patches may have as few as 4 fibres per cm others may have as many as, or more than, 100 fibres per cm depending upon the diameter of the fibres; it being necessary that the fibres be spaced apart sufficiently to penetrate the skin. Usually, the fibres will be made from material different from that of the sheet,-and in such a case, the fibres are necessarily located within the sheet as well as projecting from a face of the sheet. However, the fibres may be made of the same material as the sheet and simply project from the sheet. I
A wide variety of materials, especially plastics materials, are known which may be used to form the sheet.
Particularly useful such materials are, for example,
plasticised or unplasticised homopolymeric thermo plastics, for example polyvinylchloride, polyvinylbutyral, polyethylene, polyamides, for example nylon, or cellulosics such as cellulose acetate; plasticised or unplasticised copolymeric thermoplastics, for example ethylene vinyl acetate; cross-linked water soluble polymers, for example polyvinylacetate or polyvinylpyrrolidone; rubbers, both natural and synthetic, for example polyisobutylene or polybutadiene; or foams, for example polyurethane foam, polyester foam or cellulose foam. In this lattercase, the range of materials which may be used is very wide indeed, but care should be taken to choose a foam which is sufficiently rigid to support the fibres and yet sufficiently porous. Preferred plastics materials for the sheet are cellulose acetate or nylon.
The sheet mayalso be made of metal, for example stainless steel, which may either be provided with fibres in the form of fine stainless steel tubes or projections of metal left round the edges of holes punched in the metal sheet. Alternatively a former, for example a naturally spiky material such as a nettle or delphinium leaf may be coated with a metal to give a pad according to the invention, or-a pad prepared from other materials may be coated with metal to strengthen the fibres.
The fibres may be made of any material the surface of which is inert to body tissue and which is sufficiently strong when in the form of tiny fibres to penetrate the stratum corneum under the conditions in which the complete dressing is used. Particularly suitable such materials are, for example, inorganic materials, for example a glass, carbon, alumina, zirconia or silicon nitride; organic materials, for example nylon or polyparabenzamide; or metals, for example stainless steel. Alternatively, a bio-degradable material may be used. The type of material chosen for any particular use will depend upon the site at which the complete dressing is to be applied,the nature of the drug to be administered and any other features associated with that particular use of the complete dressing.
In a preferred use of the pad, a reservoir of pharmacologically active material is arranged'to dispense that material on to that surface of the pad remote from the projecting fibres. In this use, the pad must be permeable to a liquid formulation of a pharmacologically active material. This permeability may be achieved by using fibres in the form of tiny tubes, usually called capillary tubes, by using a sheet of material provided with a number of transverse holes, or by using an intrinsi of the desired liquid formulation. Any method of combination of methods of rendering the pad permeable may be used depending upon whether solid or hollow fibres are used and whether or not an intrinsically'permeable sheet is used, but the use of hollow fibres is considered to be desirable.
The precise diameter of the fibres is not critical provided that they can penetrate the stratum coneum, but it is preferred that the diameter be in the range 8 pm. to pm. unless the ends of thefibres are sharpened in which case, the diameter of the end of the fibre is preferably in the range 8 am. to 100 am. Thelength of fibre which projects from the sheet is, however, important since it must be longenough to penetrate the stratum corneum, but not be so long that serious irritation is caused. In this context, a penetration of at least 20 ,um. is desirable, and a penetration of 1,000 pm. is probably the maximum which can be tolerated, depending upon the site at which the pad is located. The fibres therefore should project from the sheet for a dis tance within the above range, and for preference; within the range 50-500 um. Clearly, the fibres should be aligned so that they project from that face of the 3 as an angle of approximately 45-90 to the face of the sheet. I
It is envisaged-that any liquid formulation of a pharmacologically active material may be used in conjunction with the pad of the invention provided that the formulation has a sufficiently low viscosity to pass through the pad by the means provided. Not only solutions, but suspensions and creams can be used with the appropriate pad. I
A pad according to the invention may be constructed by any suitable method. Thus for the construction of small pads, the fibres may be laid individually on a work base and cemented together using a solution of a plastics material as defined above to form a sheet con-v taining the fibres. Several such sheets may then be joined to form a block which on being sliced normal to the fibres, produces .a sheet containing transverse fibres. On washing the surface of such a sheet with solvent, the fibres can be exposed to any desired length. Alternatively the fibres may be drawn directly on to a drum coated with plastics material and while still on the drum coated with the sameplastics material to give a sheet similar to that produced by hand. Other techniques are the tack-spin process for producing a carpet-like pile of fibres, modified whereby a micro-mesh grid is usedto draw a plastics material in the molten state into a pad of fibres, orthe flock-spraying process for depositing whiskers of organic or inorganic material upon a plastics backing.
A pad according to the invention can be'used to assist the absorption of a topically applied formulation of a pharmacologically active material, for example a cream or gel, by being placed over the applied formulation. In this case, of course, the pad need not be permeable. However the principal use envisaged for a pad according to the invention is as part of a dressing for the administration of a pharmacologically active material to man or an animal.
According to a further feature of the invention there is provided a dressing for the administration of a pharmacologically active material to a host comprising a pad as previously defined in accordance with the invention in'which the pad is permeable to a liquid formulation of a pharmacologically active material, and a reservoir fora liquid formulation of a pharmacologically active material so located that the pharmacologically active material, when present, can pass from the reservoir and through the pad.
In order that this aspect of the invention may be clearly understood, two simple embodiments of a dressing according to the invention will now be described with reference to the accompanying drawings of which:
FIG. Iis'a diagrammatic representation of a vertical section of one embodiment I and I FIG. II is a diagrammatic representation of a vertical section of another embodiment. I Referring first to FIG. I, the dressing comprises a relatively rigid case I of metal or hard plastics material in the shape of an inverted shallow dish provided with a rim 2. Across the case 1, approximately in line with the rim 2, is a pad according to the invention in the form of a sheet of plastics material 3, provided with tiny fibres 4 projecting from the lower face of the sheet 3. As illustrated, the projection of the fibres 4 from the sheet 3 is much exaggerated in order'to render it visible. Particular pads which may be in the dressing are illustrated in theaccompanying Example 1-6, and in the event of such a pad not being permeable to a formulation of pharmacologically active material by virtue of the permeability of the sheet or the fibres being hollow, the pad is made permeable by being pierced in 5-10 places. If necessary, such intrinsic permeability is augmented by holes pierced through t h e pad. The space formed between the pad and the case 1 forms a reservoir 5, and .at the upper part of case 1 (the base of the inverted dish) is located a means for filling the reservoir in the form of ahole which is closed by a plug 6, made of relatively soft material, for example'neoprene, which is capable of re-sealing after a needle has been passed through and then withdrawn from the plug. Secured to the case 1 are straps 7 which extend from each side of the case 1. v
I In use, the dressing is secured upon the skin of the host to whom a phannacologically active material is to be administeredby means of the straps 7 so'that the fibres 4, projecting from the sheet 3 are held against the surface of the skin. A liquid formulation of the pharmacologically active materiaL'usually in the form of a solution, is filled into the reservoir 5 through the needle of a hypodermic syringe inserted through the plug 6.
When the reservoir 5 is filled,-the' needle is withdrawn and the plug re-seals. The dressing is .then left in place on the skin of the host until sufficient pharmacolog-' the skin of the host. I I
Referring now to FIG. II, the dressing illustrated is ically active material has been administered through similar to that of FIG. I in that it comprises a relatively I rigid case 1, and a pad, formed from a sheet of plastics material 3 with fibres 4, forming a reservoir 5 which can be filled with a liquid formulation of a pharmacologically active material via a plug 6 located in the side wall of the case 1. The dressing of FIG. II is however provided with means for applying pressure to the formulation of pharmacologically active material, when such is present in the reservoir 5, in the form of a chamher 8 in theupper part of the case 1, separated from the reservoir 5 by a flexible membrane'9, and capable of retaining gas under a pressure greater than atmospheric pressure. In the particular embodiment of FIG. II, the chamber 8 can contain granules of sodium bicarbonate, preferably coated with a polymer, so that on admitting an acidic solution to the chamber 8 via the needle of a hypodermic syringe inserted through the plug 10, carbon dioxide gas is slowly generated and a pressure is exerted on the-membrane 9. I
The embodiment of FIG. II is used in the same way as that of FIG. I, being secured to the host by straps 7.
Clearly the two embodiments illustrated represent.
only particular examples of dressings'according to the invention, and many variations of detail can be envisaged.
Thus the reservoir may be distinct from the pad, for example the walls of the reservoir may be separate from the case and/or the pad. The reservoir could be, for example, a sachet of plastics material permeable to the liquid formulation of the pharmacologically active material and located within the space formed by the case and the pad in the embodiments illustrated, or it could be formed from the case and a permeable .wall extending across the case along, the inside of the pad. Alternatively, it could be in the form of, for example,
a foam in which a solution of the pharmacologically active material can beretained by capillary action; a capsule which can be filled with pharmacologically active material to be pierced with a needle when it is desired to admit that material to the pad; or a piece of wadding which may be impregnated with the desired pharmacologically active'material. As yet a further alternative, the reservoir may be a gel which may be impregnated with pharmacologically active material as desired.
When the dressing is provided with pharmacologically active material and is in use, that material will diffuse from the reservoir to the pad, and the rate at which this takes place isdependent upon the nature of the reservoir wall and its thickness, both of which can be varied as desired. In the cases illustrated where the pad itself forms one wall of the reservoir, the rate of diffusion is dependent upon the pad and its fibres.
The dressing may also be provided with a layer of ma terial between the reservoir and the pad to act as a diffusion layer to control the rate of delivery of the pharmacologically-active material to the pad.
As illustrated in FIG. II, the dressing may also be provided with means whereby pressure is exerted on the formulation of pharmacologically active material toincrease the rate at. which it passes from the reservoir and/or through the pad. Alternatives to the specific means illustrated are, for example, a distendible reservoir which can be filled under pressure; a spring-loaded reservoir which exerts a mechanical or hydrostatic pressure on its contents; or a pressure bandage which is used both to retain the dressing in place and to exert pressure on the contents of the reservoir.
In addition, or as an alternative to, a pressure bandage, the dressing may be secured to the skin of a host by means of adhesive tape or an elasticated net, and such securing means may form part of the dressing itself. As part of the securing means of the dressing, in order to prevent undue leakage of the formulation of pharmacologically active material from the periphery of the area of skin to which the pad is pressed, the area surrounding the pad, for example the rim 2 in the embodiments illustrated or partof the straps 7, may bear an adhesive tosecure that area to the skin of the host.
As indicated above, the rate of diffusion of the liquid formulation of pharmacologically active material from the reservoir to the host is dependent upon the nature of the reservoir and the nature of the pad. Clearly, the total amount of material administered to the host is also dependent upon the surface area of the reservoir and pad. When an extremely potent drug is to be administered, a small surface area only is required, and the pad may have an area of only a few cm Forless potent materials, where administration of a larger amount of material is necessary, a greater surface area is needed and the dressing may be large enough," say to cover the whole of a patients forearm or a major part of the abdomen.
It will be clear that a dressing according to the present invention, as well as being capable of being used to administer pharmacologically active materials normally given by injection, can also be used to administer such materials continuously over an extended period. Such amethod of administration enables the variation in the concentration of a pharmacologically active material in the blood of a host, produced by administration of the material at intervals, to be reduced, and this advantage is not limited to materials which are normally administered by injection.
tides, for example polypeptide hormones and synthetic polypeptides possessing some at least of the pharmacological properties of the hormones, for example insulin,
oxytocin, bradykinin, gastrin, pentagastrin or urogastrone; or prostaglandins.
As a further feature of the invention there is provided a dressing as defined together with aliquid formulation of a pharmacologically active material. 7
Pads according to the invention are illustrated by the following Examples, and such pads may be tested for efficacy by comparing the transfer of a solution containing a pharmacologically active material through skin in the presence of the pad with the transfer effected in its absence. Both in vitro and in vivo methods may be used. The following is an example of such a test:
. A pad, prepared as described in Example 2, was applied to a clipped and shaved area on the back of a rabbit and secured in place by a rubber pad containing a 2 cm. diameter hole in register with the prepared area of the pad. One ml. of a solution of C radio labelled 3-t-butylaminol 5-propionamido-naphthl -yloxy )2- propanol, a B-adre'nergic blocking agent. in water containing 0.74 mg./ml. was applied to the pad uniformly over a period of 5 hours. Blood samples were taken at regular intervals from the ear of the rabbit and the amount of radioactive drug present measured using a scintillation counter. The experiment was repeated in the absence of the pad and again with the stratum corneum of the skin removed by a hand dermatome. The following results were obtained:
Peak blood concentration observed Application to:
Skin less than 2-3 ngJml. Pad prepared as in Ex. 2 l4 ngJml. Skin minus straum corneum 48 ng./ml.
These results show that the pad increased the absorption of the pharmacologically active'material through the stratum corneum from an extent giving a negligible peak blood concentration to nearly one third of that obtainable when the stratum corneum was absent.
EXAMPLE 1 Fibres, in the form of glass capillary tubes 40 pm. in external diameter and approximately 15 cm. long, were laid individuallyon a glass plate parallel to each other and about 0.5 mm. apart. The ends of the tubes were retained on two strips of double-sided adhesive tape located approximately 13 cm. apart. A solution in acetone of cellulose acetate containing acetyl triethyl citrate as plasticiser was brushed on to the aligned glass tubes and the solvent allowed to evaporate. The process was repeated until a film 0.5l mm. thick had been built up. Several such films were prepared and cut into squares approximately 2.5 cm. X 2.5 cm. The faces of these squares were then brushed with acetone and laid on top of each other with the tubes all pointing in the same direction. Pressure'was applied to the stack of film for several hours, causing the individual squares of film to adhere together to form a cube. This cube was then sliced with a microtomenormal to the axis of alignment of the tubes to produce small sheets of material about 1-2 mm. thick containing glass capillary tubes arranged at 1 mm. intervals across the thickness of the sheet. One face of a small sheet was then etched away by alternately brushing that surface with acetone and then with water until about 100p.m. of glass capillary tube was exposed projecting from the surface of the sheet.This condition usually took some 30-40 applications of acetone and water to achieve and the extent of projection of the tubes was checked by examination of the sheet under a microscope using oblique illumination. In order to avoid blockage of the capillary tubes, air was blown through the pad during the etching process, and this was conveniently achieved by clamping the pad over the surface of a fine ground glass funnel through which air was being blown.
The product was a square of cellulose actate sheet having a centre portion 2 cm. in diameter provided with tiny glass capillarytubes about 0.5 mm. apart extending through the sheet and projecting from one surface by about 100 um.
I g EXAMPLE 2 q The procedure described in Example 1 was repeated except that solid glass fibres'40 pm. in diameter were a. EXA B E:
A platinum crucible was filled with small spheres of E-glass and the whole heated to l,O C. to melt the glass. The crucible was then maintained at l,200 C. for about 2 hours after which the glass was ready tobe drawn into a fibre on a rotating drum. The drum was first coated with a layer of plastics material, usually cellulose acetate, by application of a solution of the plastics material in acetone to the surface of the drum and evaporation of the'acetone. A fibre of glass was then drawn from the tip of the crucible and wound on to the drum through a guide. The drum was rotated, and the guide'wasallowed to traverse the coated surface of the drum at a speed to give the required density of wound fibre, usually 1 fibre/mm. The fibre was then cut, and a coat of plastics material applied to the wound fibre using asolution in acetone. After the acetone had evaporated, the film of plastics material with the glass fibres aligned within it was stripped from the drum. The operation was repeated many times, and then all the sheets so obtained were then interleaved with sheets of the same. plastics material of the same thickness but not containing glass fibres. The sheets were treated with a small amount of acetone and/or methanol as solvent, and by applying pressure to the sheets, a block was built up in which the glass fibres were all aligned in the same direction and evenly spaced apart. The block was then sectioned transverse to the glass fibres to give small sheets of material about 1-2 mm. thick containing glass fibres at approximately 90 to the plane of the sheet and evenly spaced apart. One surface of the sheet was then etched away using a mixture of acetone and methanol, conveniently 60-70 percent v/v of acetone, to leave the glass fibresprojecting from the surface of the sheet. A particularly convenient technique for etching a numberof such sheets was to secure such sheets to the circumference of a wheel and, by rotation of the Plastics Solid or Diameter Projection of Material Hollow glass of fibre i ibrefrmn fibre plastics sheet Cellulose acetate solid pm. 5a 150 urn. containing acetyl V 140-340 1.1m. triethyl citrate 7 66-180 51 as plasticiser (L300 mp 100-300 pm.
I 80-240 ,tm. 120-340 [.Lf'll. 1 10 pin. ca. 150 um. hollow 40-60 [LIT], Ca. 150 um. nylon* solid 40 gm. 3 @400 m.
wheelQallow the sheets to rub against one or more brushes loaded with solvent.
In this technique, the diameter of the, drawn fibre could be varied by variation in the speed of rotation of the drawing drum. Thus typically, a drawing'speed of 0.5 metre/sec. produced a fibre of about 40 um. diameter, and a drawing speed of 3 metres/sec. produced a fibre of 15 pm. diameter. 0
Also, the extent of projection of the fibre from the surface of the sheet of plastics material could be varied by controlling the extent of the etching of the plastics material. In any particular pad, the fibres did not all project to the same extent, but nevertheless, a variation in average projection from about pm. to 250 ptm., with individual variation from 50 pm. to 400 um. could be achieved. r
In a variation of the above technique, a glass tube of approximately 1 mm. external diameter was drawn through a heater at 800 C. and wound on to a drum coated with plastics material asabove. By following the above general procedure, sheets of plastics material provided with tiny, projecting hollow glass fibres were produced.
By using the techniques described above. a considerable variety of pads'comprising a sheet of plastics material provided with a multitude of tiny glass fibres projecting from one face, thereof have been preparedjA representative selection of such pads is set out below:
* 1n the case of pads made with nylon as the plastics material. the sheets without glass fibres were obtained by compression moulding instead of by evaporation ofa solution. and the pads were etched with methanol.
. j The procedure described in Ex'amp1e l was repeated using hollow nylon fibres of 50 pan. external diameter or carbon fibres of 10 um. diameter to give pads of cellulose acetate provided with tiny hollow nylon or carbon fibres projecting to about 1.5 pun. from the-surface.
. v.1; EKAMBUQ... V. v
A sheet of EN 58B stainless steel. 26 am. in thickness was cut into discs about 1.5 cm. in diameter and 20 holes punched into each disc by means of a sewing needl mounted in the chuck of a bench drill which was lowereii filfoiifirotatiohIiii'tothe steel'disc to a controlled extent. The holes so produced were 78 pm. in diameter and a burr 104 pm. in length was left projecting from one side of the steel sheet. The net result was a pad, consisting of a sheet of steel provided with tiny fibre-like spikes projecting from one surface, and being permeable to liquid by virtue of the holes.
' EXAMPLE 6 the base, each 200 pm. in diameter. Fine steel tubes 200 pm. in external diameter, 100 pm. in internal diameter were sharpened at one end and then cemented into the holes leaving 150 pm. of sharpened tube projecting from the lower face of the base of the dish. The net result was a pad of stainless steel provided with fibre-like sharpened hollow steel tubes projecting from one surface.
What we claim is:
l. A pad for augmenting the absorption of a liquid formulation of a pharmacologically active material through the skin of a host comprising a sheet of material, a plurality of tiny hollow fibres passing through the sheet and projecting from at least one face of said sheet, said fibres having an external diameter at the end of the fibre in the range 8 pm. to 100 um. and projecting from said sheet from 20 pm. to 1,000 ;.m and a means on one side of said sheet material constituting a means for supplying said liquid material.
2. A pad according to claim 1 wherein the sheet is provided with a multitude of said tiny hollow fibres.
3. A pad according to claim 1 wherein the fibres are composed of glass.
4. A pad according to'claim 3 wherein the sheet is made from cellulose acetate.
5. A dressing for administering a liquid formulation of a pharmacologically active material to a host through the skin of said host, comprising a pad according to claim 1 said supply means comprising a reservoir for receiving a liquid formulation of the phannacologically active material located to permit said liquid formulation, when present, to pass from said reservoir and through said pad to the skin of said host.
6. A dressing according to claim 5 wherein the reservoir comprises a case with the pad forming one wall.
7. A dressing according to claim 5 which additionally includes pressure applying means for increasing the pressure in the reservoir.
8. A dressing according to claim 5 which additionally includes securing means for attaching the dressing to the skin of the host.
9. A dressing according to claim 5 wherein the reservoir contains a plug for the insertion of a means for supplying said liquid formulation of the pharmacologically active material.
10. A dressing according to claim 9 wherein the pharmacologically active material is a polypeptide.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US25637 *||4 Oct 1859||Cooking-stove|
|US3023750 *||4 Mar 1959||6 Mar 1962||Howard C Baron||Self-generating pressure device for infusion administration systems|
|US3062212 *||8 Aug 1960||6 Nov 1962||Harvey Kravitz||Vaccinating devices|
|US3072122 *||15 Jan 1959||8 Jan 1963||Roy Rosenthal Sol||Package for transcutaneous injection|
|US3167073 *||16 Jan 1962||26 Jan 1965||Roy Rosenthal Sol||Transcutaneous injection device|
|US3416530 *||2 Mar 1966||17 Dec 1968||Richard A. Ness||Eyeball medication dispensing tablet|
|US3545439 *||4 Jan 1968||8 Dec 1970||Upjohn Co||Medicated devices and methods|
|US3565075 *||2 May 1968||23 Feb 1971||Jerry Frederick Lonnie||Bandage|
|US3595231 *||17 Feb 1969||27 Jul 1971||A Guerin Soc||Device for simultaneously injecting a liquid at a plurality of injection points|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4026290 *||18 Nov 1975||31 May 1977||Fisons Limited||Method of administering medicaments through the skin|
|US4036229 *||24 Oct 1975||19 Jul 1977||Rosolino Marinello||Apparatus for assisting the treatment of wounds or inflammations internal to the human body|
|US4340048 *||28 Mar 1981||20 Jul 1982||Alza Corporation||Self-driven hypodermic injector|
|US4439199 *||25 Mar 1982||27 Mar 1984||Alza Corporation||Method for administering immunopotentiator|
|US4455142 *||11 Jan 1982||19 Jun 1984||Alza Corporation||Method of coadministering an antigen and an immunopotentiator|
|US4473083 *||14 Dec 1981||25 Sep 1984||Maganias Nicholas H||Device and method for allergy testing|
|US4484923 *||5 Jan 1984||27 Nov 1984||Alza Corporation||Method for administering immunopotentiator|
|US4655766 *||17 Apr 1986||7 Apr 1987||Alza Corporation||Fluid imbibing pump with self-regulating skin patch|
|US4787888 *||1 Jun 1987||29 Nov 1988||University Of Connecticut||Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)|
|US4802493 *||17 Feb 1987||7 Feb 1989||Maganias Nicholas H||Device and method for allergy testing|
|US4879275 *||27 May 1988||7 Nov 1989||Nelson Research & Development Co.||Penetration enhancers for transdermal delivery of systemic agent|
|US4920101 *||30 Sep 1987||24 Apr 1990||Nelson Research & Development Co.||Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes|
|US5000746 *||11 Aug 1988||19 Mar 1991||Friedrichsfeld Gmbh Keramik- Und Kunststoffwerke||Wound covering having connected discrete elements|
|US5034386 *||17 Aug 1988||23 Jul 1991||Whitby Research, Inc.||Methods for administration using 1-substituted azacycloalkanes|
|US5060642 *||5 Jan 1990||29 Oct 1991||Gilman Thomas H||Wound dressing with air permeable bacteria impermeable reservoir|
|US5122127 *||5 Sep 1989||16 Jun 1992||University Of Utah||Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues|
|US5204339 *||6 Aug 1990||20 Apr 1993||Whitby Research, Inc.||Penetration enhancers for transdermal delivery of systemic agents|
|US5399683 *||19 May 1993||21 Mar 1995||Inflazyme Pharmaceuticals, Inc.||Mirror amide cord factors and mirror thioester cord factors for diagnosis of tuberculosis|
|US5423778 *||11 Jun 1992||13 Jun 1995||Elof Eriksson||System and method for transplantation of cells|
|US5661132 *||22 Nov 1994||26 Aug 1997||Auragen, Inc.||Wound healing|
|US5697901 *||19 May 1995||16 Dec 1997||Elof Eriksson||Gene delivery by microneedle injection|
|US5983136 *||15 Sep 1997||9 Nov 1999||Deka Products Limited Partnership||System for delivery of drugs by transport|
|US6050988 *||9 Dec 1998||18 Apr 2000||Alza Corporation||Device for enhancing transdermal agent flux|
|US6083196 *||9 Dec 1998||4 Jul 2000||Alza Corporation||Device for enhancing transdermal agent flux|
|US6091975 *||1 Apr 1998||18 Jul 2000||Alza Corporation||Minimally invasive detecting device|
|US6219574 *||17 Jun 1997||17 Apr 2001||Alza Corporation||Device and method for enchancing transdermal sampling|
|US6322808||9 Dec 1998||27 Nov 2001||Alza Corporation||Device for enhancing transdermal agent flux|
|US6454755 *||24 Apr 1997||24 Sep 2002||Silicon Microdevices||Method and apparatus for transdermal delivery of compounds utilizing disruption of the epidermis|
|US6537264 *||16 Dec 1999||25 Mar 2003||Alza Corp||Device and method for enhancing transdermal flux of agents being sampled|
|US6562014||14 Dec 2000||13 May 2003||Alza Corporation||Device and method for enhancing transdermal flux of agents being sampled|
|US6623457||22 Sep 1999||23 Sep 2003||Becton, Dickinson And Company||Method and apparatus for the transdermal administration of a substance|
|US6629949 *||29 Sep 2000||7 Oct 2003||Sterling Medivations, Inc.||Micro infusion drug delivery device|
|US6659982||1 May 2001||9 Dec 2003||Sterling Medivations, Inc.||Micro infusion drug delivery device|
|US6690959||31 Aug 2001||10 Feb 2004||Medtronic, Inc.||Skin-mounted electrodes with nano spikes|
|US6780171||2 Apr 2002||24 Aug 2004||Becton, Dickinson And Company||Intradermal delivery device|
|US6855131||12 Oct 2001||15 Feb 2005||Alza Corporation||Microprotrusion member retainer for impact applicator|
|US6855372||15 Mar 2002||15 Feb 2005||Alza Corporation||Method and apparatus for coating skin piercing microprojections|
|US6918901||10 Dec 1997||19 Jul 2005||Felix Theeuwes||Device and method for enhancing transdermal agent flux|
|US6953589||4 Oct 2000||11 Oct 2005||Alza Corporation||Device for enhancing transdermal agent flux|
|US7066922||21 Oct 2002||27 Jun 2006||Massachusetts Institute Of Technology||Transdermal transport device with suction|
|US7070580||1 Apr 2003||4 Jul 2006||Unomedical A/S||Infusion device and an adhesive sheet material and a release liner|
|US7087035||8 Dec 2000||8 Aug 2006||Alza Corporation||Device and method for enhancing skin piercing by microprotrusions|
|US7094422||20 Aug 2003||22 Aug 2006||Acrux Dds Pty Ltd.||Topical delivery of antifungal agents|
|US7097631||21 Oct 2004||29 Aug 2006||Alza Corporation||Self-actuating applicator for microprojection array|
|US7115108||2 Apr 2002||3 Oct 2006||Becton, Dickinson And Company||Method and device for intradermally delivering a substance|
|US7115112||1 Sep 2003||3 Oct 2006||Unomedical A/S||Device for subcutaneous administration of a medicament to a patient and tubing for same|
|US7131960||12 Oct 2001||7 Nov 2006||Alza Corporation||Apparatus and method for piercing skin with microprotrusions|
|US7147623||11 Feb 2003||12 Dec 2006||Unomedical A/S||Infusion device with needle shield|
|US7182747||21 Nov 2005||27 Feb 2007||Theraject, Inc.||Solid solution perforator for drug delivery and other applications|
|US7184826||17 Jun 1997||27 Feb 2007||Alza Corporation||Device and method for enhancing transdermal flux of agents being delivered or sampled|
|US7211062||28 Jan 2004||1 May 2007||Theraject, Inc.||Solid solution perforator for drug delivery and other applications|
|US7214221||26 Mar 2003||8 May 2007||Becton, Dickinson And Company||Multi-stage fluid delivery device and method|
|US7250037||22 Jul 2003||31 Jul 2007||Becton, Dickinson And Company||Patch-like infusion device|
|US7258680||1 Sep 2003||21 Aug 2007||Unomedical A/S||Device for subcutaneous administration of a medicament to a patient|
|US7364568||21 Oct 2002||29 Apr 2008||Massachusetts Institute Of Technology||Microneedle transdermal transport device|
|US7410476 *||8 Jul 2005||12 Aug 2008||Becton, Dickinson And Company||Method and device for intradermally delivering a substance|
|US7419481||28 Mar 2005||2 Sep 2008||Alza Corporation||Apparatus and method for piercing skin with microprotrusions|
|US7422574||25 Feb 2003||9 Sep 2008||Applied Tissue Technologies, Llc||Microseeding device for gene delivery by microneedle injection|
|US7429258||9 Sep 2002||30 Sep 2008||Massachusetts Institute Of Technology||Microneedle transport device|
|US7435299||9 Nov 2004||14 Oct 2008||Alza Corporation||Method and apparatus for coating skin piercing microprojections|
|US7438926||8 Sep 2001||21 Oct 2008||Alza Corporation||Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure|
|US7455654||21 Oct 2004||25 Nov 2008||Alza Corporation||Method and apparatus for reducing the incidence of tobacco use|
|US7473247||2 Oct 2003||6 Jan 2009||Becton, Dickinson And Company||Intradermal delivery of vaccines and gene therapeutic agents via microcannula|
|US7481794||9 Sep 2005||27 Jan 2009||Unomedical A/S||Cover|
|US7537795||26 Oct 2001||26 May 2009||Alza Corporation||Transdermal drug delivery devices having coated microprotrusions|
|US7556821||18 Mar 2005||7 Jul 2009||Alza Corporation||Apparatus and method for transdermal delivery of parathyroid hormone agents|
|US7579013||29 Jun 2004||25 Aug 2009||Alza Corporation||Formulations for coated microprojections containing non-volatile counterions|
|US7594909||2 Sep 2003||29 Sep 2009||Unomedical, A/S||Apparatus and method for adjustment of the length of an infusion tubing|
|US7621395||8 Jun 2006||24 Nov 2009||Unomedical A/S||Packing for infusion set and method of applying an infusion set|
|US7645263||21 Oct 2002||12 Jan 2010||Massachusetts Institute Of Technology||Impedance sensor|
|US7648494||21 Mar 2005||19 Jan 2010||Unomedical A/S||Infusion set and injector device for infusion set|
|US7651475||11 Jan 2008||26 Jan 2010||Massachusetts Institute Of Technology||Microneedle transport device|
|US7654484||2 Sep 2003||2 Feb 2010||Unomedical A/S||Apparatus for and a method of adjusting the length of an infusion tube|
|US7658728||10 Jan 2006||9 Feb 2010||Yuzhakov Vadim V||Microneedle array, patch, and applicator for transdermal drug delivery|
|US7678079||25 Apr 2007||16 Mar 2010||Becton, Dickinson And Company||Patch-like infusion device|
|US7722595||6 May 2003||25 May 2010||Becton, Dickinson And Company||Method and device for controlling drug pharmacokinetics|
|US7785301||28 Nov 2006||31 Aug 2010||Vadim V Yuzhakov||Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection|
|US7798987||28 Mar 2005||21 Sep 2010||Alza Corporation||Apparatus and method for piercing skin with microprotrusions|
|US7802824||26 Nov 2003||28 Sep 2010||Unomedical A/S||Connecting piece for a tubing|
|US7857131||12 Aug 2004||28 Dec 2010||Becton, Dickinson And Company||Patch-like infusion device|
|US7867199||9 Dec 2005||11 Jan 2011||Unomedical A/S||Inserter|
|US7867200||9 Dec 2005||11 Jan 2011||Unomedical A/S||Inserter|
|US7896837 *||3 Jul 2008||1 Mar 2011||Becton, Dickinson And Company||Method and device for intradermally delivering a substance|
|US7914480||9 Oct 2009||29 Mar 2011||Corium International, Inc.||Transdermal delivery device|
|US7963935||20 Apr 2002||21 Jun 2011||Alza Corporation||Microprojection array having a beneficial agent containing coating|
|US7989674||30 Oct 2007||2 Aug 2011||Argentum Medical, Llc||Multilayer conductive appliance having wound healing and analgesic properties|
|US8062250||23 Dec 2004||22 Nov 2011||Unomedical A/S||Cannula device|
|US8062573||15 Sep 2003||22 Nov 2011||Theraject, Inc.||Solid micro-perforators and methods of use|
|US8093444||7 May 2007||10 Jan 2012||Argentum Medical, Llc||Multilayer conductive appliance having wound healing and analgesic properties|
|US8118791||31 Oct 2007||21 Feb 2012||Argentum Medical, Llc||Medical device|
|US8152771||15 Oct 2003||10 Apr 2012||Unomedical A/S||Injector device for placing a subcutaneous infusion set|
|US8153162||27 Sep 2006||10 Apr 2012||Tissuetech, Inc.||Purified amniotic membrane compositions and methods of use|
|US8162892||29 Mar 2004||24 Apr 2012||Unomedical A/S||Injector device for placing a subcutaneous infusion set|
|US8172805||7 Jan 2005||8 May 2012||Unomedical A/S||Injector device for placing a subcutaneous infusion set|
|US8182840||22 May 2012||Tissue Tech, Inc.||Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition|
|US8182841||27 Sep 2006||22 May 2012||Tissue Tech, Inc.||Amniotic membrane preparations and purified compositions and anti-inflammation methods|
|US8187639||29 May 2012||Tissue Tech, Inc.||Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment|
|US8216190 *||9 Feb 2006||10 Jul 2012||Corium International, Inc.||Microstructures for delivering a composition cutaneously to skin|
|US8221355||21 Mar 2005||17 Jul 2012||Unomedical A/S||Injection device for infusion set|
|US8236288||6 Jan 2012||7 Aug 2012||Skinmedica, Inc.||Melanin modification compositions and methods of use|
|US8246582||29 Apr 2008||21 Aug 2012||Massachusetts Institute Of Technology||Microneedle transdermal transport device|
|US8283513||6 Sep 2005||9 Oct 2012||Argentum Medical, Llc||Multilayer wound dressing|
|US8293964||29 Oct 2007||23 Oct 2012||Argentum Medical, Llc||Multilayer laminate wound dressing|
|US8361022||1 Jul 2009||29 Jan 2013||Alza Corporation||Apparatus for transdermal delivery of parathyroid hormone agents|
|US8414548||27 Jan 2010||9 Apr 2013||Vadim V. Yuzhakov||Method of making microneedle array and device for applying microneedle array to skin|
|US8420126||16 Apr 2013||Tissue Tech, Inc.||Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment|
|US8440235||14 May 2013||Tissuetech, Inc.||Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition|
|US8444604||12 Aug 2004||21 May 2013||Becton, Dickinson And Company||Patch-like infusion device|
|US8449514 *||29 Oct 2007||28 May 2013||Argentum Medical, Llc||Conductive wound dressings and methods of use|
|US8455009||23 Apr 2012||4 Jun 2013||Tissuetech, Inc.||Amniotic membrane preparations and purified compositions and anti-inflammation methods|
|US8455710||23 Apr 2003||4 Jun 2013||Argentum Medical, Llc||Conductive wound dressings and methods of use|
|US8460714||11 Jun 2013||Tissuetech, Inc.||Purified amniotic membrane compositions and methods of use|
|US8465468 *||29 Jun 2000||18 Jun 2013||Becton, Dickinson And Company||Intradermal delivery of substances|
|US8512287||12 Aug 2004||20 Aug 2013||Becton, Dickinson And Company||Patch-like infusion device|
|US8557251||13 Jun 2007||15 Oct 2013||Glaxosmithkline Biologicals, Sa||Non-live trivalent influenza vaccine for one-dose intradermal delivery|
|US8617487||25 Mar 2009||31 Dec 2013||Venture Lending & Leasing Vi, Inc.||Saliva sample collection systems|
|US8663155||2 Feb 2006||4 Mar 2014||Alza Corporation||Transdermal drug delivery devices having coated microprotrusions|
|US8702726||18 Oct 2010||22 Apr 2014||Corium International, Inc.||Method of exfoliation of skin using closely-packed microstructures|
|US8708994 *||28 Mar 2011||29 Apr 2014||Becton, Dickinson And Company||Method for altering drug pharmacokinetics based on medical delivery platform|
|US8753318||1 Nov 2004||17 Jun 2014||Alza Corporation||Microprotrusion member retainer for impact applicator|
|US8778315||26 Feb 2013||15 Jul 2014||Allergan, Inc.||Melanin modification compositions and methods of use|
|US8796416||25 Oct 2011||5 Aug 2014||Questcor Pharmaceuticals, Inc||ACTH prophylactic treatment of renal disorders|
|US8801681||21 Oct 2005||12 Aug 2014||Argentum Medical, Llc||Medical device|
|US8821446||22 Jan 2008||2 Sep 2014||Corium International, Inc.||Applicators for microneedles|
|US8846740||4 Jan 2012||30 Sep 2014||Biological Responsibility, Llc||Biotherapeutics for the treatment of infectious diseases|
|US8911749||10 Oct 2008||16 Dec 2014||Corium International, Inc.||Vaccine delivery via microneedle arrays|
|US8920375 *||23 Sep 2002||30 Dec 2014||Valeritas, Inc.||Gas pressure actuated microneedle arrays, and systems and methods relating to same|
|US8932539||20 Dec 2013||13 Jan 2015||Pathway Genomics Corporation||Saliva sample collection systems|
|US8945071||2 Sep 2010||3 Feb 2015||Becton, Dickinson And Company||Self-injection device having needle cover with activation preventer|
|US8957216||24 Mar 2011||17 Feb 2015||Amitech Therapeutic Solutions, Inc.||Heterocyclic compounds useful for kinase inhibition|
|US8961469||16 Dec 2009||24 Feb 2015||Becton, Dickinson And Company||Self-injection device|
|US8986280||19 Apr 2013||24 Mar 2015||Becton, Dickinson And Company||Intradermal delivery of substances|
|US8998877||19 Apr 2013||7 Apr 2015||Becton, Dickinson And Company||Intradermal delivery of substances|
|US9005182||19 Apr 2013||14 Apr 2015||Becton, Dickinson And Company||Intradermal delivery of substances|
|US9044404||26 Feb 2013||2 Jun 2015||Allergan, Inc.||Melanin modification compositions and methods of use|
|US20020016562 *||17 Jun 1997||7 Feb 2002||Michel J. N. Cormier||Device and method for enhancing transdermal flux of agents being delivered or sampled|
|US20020132054 *||15 Mar 2002||19 Sep 2002||Trautman Joseph C.||Method and apparatus for coating skin piercing microprojections|
|US20020156453 *||28 Dec 2001||24 Oct 2002||Pettis Ronald J.||Method and device for reducing therapeutic dosage|
|US20040081684 *||20 Aug 2003||29 Apr 2004||Monash University||Topical delivery of antifungal agents|
|US20040082934 *||28 Aug 2003||29 Apr 2004||Pettis Ronald J.||Method of controlling pharmacokinetics of immunomodulatory compounds|
|US20040096455 *||8 Aug 2003||20 May 2004||Yuh-Fun Maa||Transdermal vaccine delivery device having coated microprotrusions|
|US20040096463 *||21 Feb 2002||20 May 2004||Nathalie Garcon||Novel vaccine|
|US20040115167 *||29 Sep 2003||17 Jun 2004||Michel Cormier||Drug delivery device and method having coated microprojections incorporating vasoconstrictors|
|US20040120964 *||2 Oct 2003||24 Jun 2004||Mikszta John A.||Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses|
|US20040131641 *||2 Oct 2003||8 Jul 2004||Mikszta John A.||Intradermal delivery of vaccines and gene therapeutic agents via microcannula|
|US20040138610 *||24 Dec 2003||15 Jul 2004||Michel Cormier||Active agent delivery device having composite members|
|US20040138612 *||22 Jul 2003||15 Jul 2004||Shermer Charles D.||Patch-like infusion device|
|US20040158202 *||12 Feb 2003||12 Aug 2004||Soren Jensen||Cover|
|US20040175360 *||17 Mar 2004||9 Sep 2004||Pettis Ronald J.||Method for altering drug pharmacokinetics based on medical delivery platform|
|US20040199103 *||28 Jan 2004||7 Oct 2004||Sung-Yun Kwon||Solid solution perforator for drug delivery and other applications|
|US20040199123 *||1 Apr 2003||7 Oct 2004||Nielsen Jens Egebjerg||Infusion device and an adhesive sheet material and a release liner|
|US20040236271 *||29 Jun 2004||25 Nov 2004||Felix Theeuwes||Device and method for enhancing transdermal agent flux|
|US20040265365 *||29 Jun 2004||30 Dec 2004||Daddona Peter E.||Method for coating skin piercing microprojections|
|US20050008683 *||17 Mar 2004||13 Jan 2005||Becton Dickinson And Company||Method for delivering interferons to the intradermal compartment|
|US20050010193 *||6 Nov 2003||13 Jan 2005||Laurent Philippe E.||Novel methods for administration of drugs and devices useful thereof|
|US20050025778 *||1 Jul 2004||3 Feb 2005||Cormier Michel J.N.||Microprojection array immunization patch and method|
|US20050031676 *||3 Aug 2004||10 Feb 2005||Wong Patrick S.L.||Method and device for enhancing transdermal agent flux|
|US20050055010 *||6 May 2004||10 Mar 2005||Pettis Ronald J.||Method for altering insulin pharmacokinetics|
|US20050065466 *||12 Aug 2004||24 Mar 2005||Becton, Dickinson And Company||Patch-like infusion device|
|US20050065472 *||12 Aug 2004||24 Mar 2005||Cindrich Chris N.||Patch-like infusion device|
|US20050084604 *||9 Nov 2004||21 Apr 2005||Trautman Joseph C.||Method and apparatus for coating skin piercing microprojections|
|US20050089553 *||21 Oct 2004||28 Apr 2005||Cormier Michel J.||Method and apparatus for reducing the incidence of tobacco use|
|US20050089554 *||21 Oct 2004||28 Apr 2005||Cormier Michel J.||Apparatus and method for enhancing transdermal drug delivery|
|US20050096586 *||21 Oct 2004||5 May 2005||Trautman Joseph C.||Self-actuating applicator for microprojection array|
|US20050096630 *||3 Dec 2004||5 May 2005||Pettis Ronald J.||Intradermal delivery of substances|
|US20050096631 *||3 Dec 2004||5 May 2005||Pettis Ronald J.||Intradermal delivery of substances|
|US20050096632 *||3 Dec 2004||5 May 2005||Pettis Ronald J.||Intradermal delivery of substances|
|US20050106209 *||21 Oct 2004||19 May 2005||Mahmoud Ameri||Composition and apparatus for transdermal delivery|
|US20050106226 *||21 Oct 2004||19 May 2005||Cormier Michel J.||Pretreatment method and system for enhancing transdermal drug delivery|
|US20050106227 *||21 Oct 2004||19 May 2005||Samuel Zalipsky||Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections|
|US20050112135 *||21 Oct 2004||26 May 2005||Cormier Michel J.||Ultrasound assisted transdermal vaccine delivery method and system|
|US20050123507 *||12 Jan 2005||9 Jun 2005||Mahmoud Ameri||Formulations for coated microprojections having controlled solubility|
|US20050124967 *||28 Dec 2001||9 Jun 2005||Kaestner Scott A.||Method and device for delivery of high molecular weight substances|
|US20050148926 *||1 Nov 2004||7 Jul 2005||Trautman Joseph C.||Microprotrusion member retainer for impact applicator|
|US20050163711 *||14 Jun 2004||28 Jul 2005||Becton, Dickinson And Company, Inc.||Intra-dermal delivery of biologically active agents|
|US20050226922 *||18 Mar 2005||13 Oct 2005||Mahmoud Ameri||Apparatus and method for transdermal delivery of fentanyl-based agents|
|US20050234401 *||28 Mar 2005||20 Oct 2005||Trautman Joseph C||Apparatus and method for piercing skin with microprotrusions|
|US20050240154 *||20 Apr 2005||27 Oct 2005||Unomedical A/S:||Infusion set with patch|
|US20050245877 *||8 Jul 2005||3 Nov 2005||Becton, Dickinson And Company||Method and device for intradermally delivering a substance|
|US20050251088 *||15 Sep 2003||10 Nov 2005||Sung-Yun Kwon||Solid micro-perforators and methods of use|
|US20050256045 *||18 Mar 2005||17 Nov 2005||Mahmoud Ameri||Apparatus and method for transdermal delivery of parathyroid hormone agents|
|US20050256182 *||11 May 2005||17 Nov 2005||Sutter Diane E||Formulations of anti-pain agents and methods of using the same|
|US20050256499 *||3 Mar 2005||17 Nov 2005||Pettis Ronald J||Methods and devices for improving delivery of a substance to skin|
|US20050266011 *||21 Apr 2005||1 Dec 2005||Yuh-Fun Maa||Method and formulation for transdermal delivery of immunologically active agents|
|US20050271684 *||18 Mar 2005||8 Dec 2005||Trautman Joseph C||Apparatus and method for transdermal delivery of multiple vaccines|
|US20050277887 *||18 Aug 2003||15 Dec 2005||Joel Douglas||Micro infusion drug delivery device|
|US20060030811 *||3 Aug 2004||9 Feb 2006||Wong Patrick S||Method and device for enhancing transdermal agent flux|
|US20060034902 *||10 Aug 2005||16 Feb 2006||Cormier Michel J||Microprojection apparatus and system with low infection potential|
|US20110190725 *||4 Aug 2011||Becton, Dickinson And Company||Method for altering drug pharmacokinetics based on medical delivery platform|
|US20130018279 *||1 Sep 2009||17 Jan 2013||Pathway Genomics||"blood sample collection apparatus and kits"|
|DE102013107024A1||4 Jul 2013||15 May 2014||Golden Biotechnology Corporation||Methoden und Zusammensetzungen zum Behandeln, Modifizieren und Handhaben von Knochenkrebsschmerz|
|DE102013107025A1||4 Jul 2013||3 Jul 2014||Golden Biotechnology Corporation||Methoden und zusammensetzungen zur behanldung von diabetis|
|DE102013202928A1||22 Feb 2013||29 Aug 2013||Golden Biotechnology Corporation||Verfahren und Zusammensetzungen zum Behandeln von Krebsmetastasierung|
|EP0081975A2 *||8 Dec 1982||22 Jun 1983||Nicholas H. Maganias||Device and method for allergy testing|
|EP0114125A2 *||18 Jan 1984||25 Jul 1984||Almedco, Inc.||Medication application systems|
|EP1086718A1 *||7 Aug 2000||28 Mar 2001||Becton, Dickinson and Company||Method and apparatus for the transdermal administration of a substance|
|EP1674068A1||19 Feb 1997||28 Jun 2006||Acrux DDS Pty Ltd||Dermal penetration enhancers and drug delivery systems involving same|
|EP1880743A1 *||29 Jun 2001||23 Jan 2008||Becton, Dickinson and Company||Microneedle for delivering a substance into the dermis|
|EP1911488A2||9 Dec 1998||16 Apr 2008||Alza Corporation||Device for enhancing transdermal agent flux|
|EP1925333A1 *||29 Jun 2001||28 May 2008||Becton, Dickinson and Company||Intradermal delivery of substances|
|EP2085109A2||26 Oct 2001||5 Aug 2009||Alza Corporation||Transdermal drug delivery devices having coated microprotrusions|
|EP2201840A1||28 Dec 2006||30 Jun 2010||Pharmacyclics, Inc.||Inhibitors of Bruton's Tyrosine Kinase|
|EP2443929A1||28 Dec 2006||25 Apr 2012||Pharmacyclics, Inc.||Inhibitors of Bruton's Tyrosine Kinase|
|EP2526771A1||28 Dec 2006||28 Nov 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2526933A2||28 Dec 2006||28 Nov 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2526934A2||28 Dec 2006||28 Nov 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2529621A1||28 Dec 2006||5 Dec 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2529622A1||28 Dec 2006||5 Dec 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2530083A1||28 Dec 2006||5 Dec 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2532234A1||28 Dec 2006||12 Dec 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2532235A1||28 Dec 2006||12 Dec 2012||Pharmacyclics, Inc.||Inhibitors of bruton's tyrosine kinase|
|EP2650294A1||12 Oct 2010||16 Oct 2013||Pharmacyclics, Inc.||Inhibitors of Bruton's Tyrosine Kinase|
|EP2664337A1||27 Sep 2006||20 Nov 2013||TissueTech, Inc.||Amniotic membrane preparations and purified compositions and methods of use|
|WO1999029298A2||9 Dec 1998||17 Jun 1999||Alza Corp||Device for enhancing transdermal agent flux|
|WO1999029364A1||9 Dec 1998||17 Jun 1999||Alza Corp||Device for enhancing transdermal agent flux|
|WO1999029365A1||9 Dec 1998||17 Jun 1999||Alza Corp||Device for enhancing transdermal agent flux|
|WO2001041864A1||7 Dec 2000||14 Jun 2001||Alza Corp||Skin treatment apparatus for sustained transdermal drug delivery|
|WO2002002179A1 *||29 Jun 2001||10 Jan 2002||Becton Dickinson Co||Microneedle for delivering a substance into the dermis|
|WO2002030281A1||12 Oct 2001||18 Apr 2002||Alza Corp||Microblade array impact applicator|
|WO2002030300A2||12 Oct 2001||18 Apr 2002||Alza Corp||Microprotrusion member retainer for impact applicator|
|WO2002030506A2||11 Oct 2001||18 Apr 2002||Carmon Amiram||Transdermal method|
|WO2002094368A1 *||26 Oct 2001||28 Nov 2002||Alza Corp||Transdermal drug delivery devices having coated microprotrusions|
|WO2003084598A1 *||31 Mar 2003||16 Oct 2003||Becton Dickinson Co||Method and device for intradermally delivering a substance|
|WO2004030743A2||29 Sep 2003||15 Apr 2004||Alza Corp||Drug delivery device having coated microprojections incorporating vasoconstrictors|
|WO2004060473A2||24 Dec 2003||22 Jul 2004||Alza Corp||Active agent delivery device having composite members|
|WO2005004842A2||29 Jun 2004||20 Jan 2005||Alza Corp||Formulations for coated microprojections containing non-volatile counterions|
|WO2005042054A2||21 Oct 2004||12 May 2005||Alza Corp||Pretreatment method and system for enhancing transdermal drug delivery|
|WO2005051476A1 *||26 Nov 2004||9 Jun 2005||Acrux Dds Pty Ltd||Method and system for rapid transdermal administration|
|WO2007062266A2||28 Nov 2006||31 May 2007||Marinus Pharmaceuticals||Ganaxolone formulations and methods for the making and use thereof|
|WO2008021368A2||13 Aug 2007||21 Feb 2008||Norman Haughey||Compositions and methods for neuroprotection|
|WO2008039218A2||28 Dec 2006||3 Apr 2008||Pharmacyclics Inc||Inhibitors of bruton's tyrosine kinase|
|WO2008066899A2||28 Nov 2007||5 Jun 2008||Marinus Pharmaceuticals||Nanoparticulate formulations and methods for the making and use thereof|
|WO2010071866A2||19 Dec 2009||24 Jun 2010||Nuon Therapeutics, Inc.||Combination therapy for arthritis with tranilast|
|WO2011139489A2||11 Apr 2011||10 Nov 2011||Calcimedica Inc.||Compounds that modulate intracellular calcium|
|U.S. Classification||604/304, 600/556, 423/563|
|International Classification||A61K9/70, A61F13/00, A61M37/00|
|Cooperative Classification||A61M2037/0023, A61F13/00063, A61K9/0021, A61M2037/0007, A61F13/00068, A61F2013/0017, A61M37/0015|
|European Classification||A61M37/00M, A61F13/00B6, A61F13/00B8, A61K9/00M5B|